Aligos Therapeutics Inc. (ALGS) News
Filter ALGS News Items
ALGS News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
ALGS News Highlights
- ALGS's 30 day story count now stands at 2.
- Over the past 13 days, the trend for ALGS's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
- The most mentioned tickers in articles about ALGS are ALG, DEC and CABO.
Latest ALGS News From Around the Web
Below are the latest news stories about ALIGOS THERAPEUTICS INC that investors may wish to consider to help them evaluate ALGS as an investment opportunity.
Aligos Therapeutics Presents Positive Clinical Data at Hep-DART 2023 from Phase 1 Studies in HBV (ALG-000184) and NASH (ALG-055009)SOUTH SAN FRANCISCO, Calif., Dec. 07, 2023 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in liver and viral diseases, delivered oral presentations of clinical data for its capsid assembly modulator-empty (CAM-E), ALG-000184, and its thyroid hormone receptor-beta (THR-β) drug candidate, ALG-055009, at the Hep-DART 2023 meeting, held in Cabo San Lucas, Mexico, from Dec |
13 Stocks Insiders are Buying NowIn this article, we will take a look at the 13 stocks insiders are buying now. To see more such companies, go directly to 5 Stocks Insiders are Buying Now. With the end of 2023 now in sight, many can say with confidence that the much-dreaded recession everyone was talking about will not realize this […] |
Why Is Aligos Therapeutics (ALGS) Stock Down 5% Today?Aligos Therapeutics stock is falling alongside news of a secondary offering for ALGS that it won't see any proceeds of the sales from. |
Why Is Tharimmune (THAR) Stock Down 8% Today?Tharimmune stock is falling after the company announced a reverse stock split for THAR shares that goes into effect later today. |
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on MondayIt's time to start the week with a breakdown of the biggest pre-market stock movers traders need to watch on Monday morning! |
Aligos Therapeutics To Present at the Piper Sandler Healthcare ConferenceSOUTH SAN FRANCISCO, Calif., Nov. 20, 2023 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in liver and viral diseases, today announced that Lawrence M. Blatt, Ph.D., MBA, Chairman and CEO of Aligos, and the Aligos management team, will present at the 2023 Piper Sandler Healthcare Conference being held in New York on Thursday, November 30, 2023 at 12:30 p.m. |
Aligos Therapeutics Presents Clinical and Nonclinical Data at the AASLD Liver Meeting® 2023 Demonstrating that ALG-055009 has a Favorable Risk-Benefit ProfileThe thyroid hormone receptor-beta (THR-b) drug ALG-055009: Was well tolerated when oral daily doses up to 1.0 mg were given for 2 weeks in a Phase 1 study in hypercholesterolemic subjects Demonstrated favorable PK with low variabilityDose responsively lowered lipid levels in study subjects Was well tolerated in animals following repeated daily dosing in 13 week toxicology studies Is more b selective and 5-47x more potent than resmetirom and VK-2809 parent Has a favorable overall risk-benefit pro |
Aligos Therapeutics Presents Positive Data at the AASLD Liver Meeting® 2023 Demonstrating that Treatment with ALG-000184 (CAM-E) Results in Significant Multi-log Reductions in Hepatitis B Antigens (HBsAg, HBcrAg and HBeAg)Hepatitis B virus e antigen positive (HBeAg+) subjects dosed with once-daily 300mg ALG-000184 + entecavir for up to 48 weeks demonstrated: Dose dependent mean reductions of up to 2 log10 IU/mL for HBV antigensMean DNA reductions of up to 6.8 log10 IU/mL No viral DNA breakthroughs in subjects receiving ALG-000184 monotherapyData suggest ALG-000184 may lower cccDNA levels via both mechanisms of action for CAM-E drugsA well tolerated safety profile SOUTH SAN FRANCISCO, Calif., Nov. 10, 2023 (GLOBE |
Aligos Therapeutics to Present Multiple Posters at AASLD’s The Liver Meeting® 2023, Highlighting Progress for Its Clinical Stage Portfolio, including Lead THR-β Agonist for the Treatment of NASH, ALG-055009; ALG-000184, the Company’s Lead CAM-E Molecule, and Updates on Several Preclinical Candidates for the Treatment of Chronic Hepatitis B, in Addition to the Recently Announced Late Breaker Poster (#5028-C)SOUTH SAN FRANCISCO, Calif., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in liver and viral diseases, today announced that the company is presenting six posters at the American Association for the Study of Liver Diseases’ (AASLD) The Liver Meeting® 2023, taking place in Boston, Massachusetts, November 10 – 14, 2023. The posters, which includ |
Aligos Therapeutics to Host KOL Event to Discuss ALG-000184 Phase 1, AASLD Late Breaker DataNovember 16 Event to feature KOL perspective on Emerging HBV TherapiesSOUTH SAN FRANCISCO, Calif., Nov. 03, 2023 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in liver and viral diseases, today announced that announced that it will host a virtual KOL event featuring Mark Sulkowski, MD, Professor of Medicine at the Johns Hopkins University School of Medicine, to revie |